Summary
Most biologic effects of immune complexes are mediated through the activation of the complement system. The relationship between lupus disease activity and the presence of C3 breakdown products (C3d) and circulating immune complexes (CIC) as demonstrated with the C1q binding assay (C1qbA), was evaluated. Nearly all 13 systemic lupus erythematosus (SLE) patients had a stable disease course in this prospective study, nevertheless, in each patient the profiles of the serologic parameters were quite different. Despite the small number of investigated patients (13), it is concluded that irrespective of the disease activity, the serologic parameters could be either positive or negative. No relationship could be obtained between disease activity and the presence of C3d and/or CIC. Nor was there any evidence that the presence of CIC would indicate increased levels of C3 breakdown products (C3d). This observation argues against a pathogenetic significance of CIC detected by the C1qbA in SLE. In conclusion, the supposed link between the presence of CIC, consumption and activation of the complement system, and the activity of SLE needs further study.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Dixon FJ, Oldstone MBA, Tonietti G (1971) Pathogenesis of immune complex glomerulonephritis of New Zealand mice. J Exp Med 134:65S-71S
Agnello V, Koffler D, Kunkel HG (1973) Immune complex systems in the nephritis of systemic lupus erythematosus. Kidney Int 3:90–99
Tan EM (1976) Immunopathology and pathogenesis of cutaneous involvement in systemic lupus erythematosus. J Invest Dermatol 67:360–365
Koffler D, Agnello V, Thoburn R, Kunkel HG (1971) Systemic lupus erythematosus: Prototype of immune complex nephritis in man. J Exp Med 134:169–179
Dienstag JL, Rhodes AR, Bahn AK, Dvorak AM, Mihm MC, Wands JR (1978) Urticaria associated with acute viral hepatitis type B. Studies of pathogenesis. Ann Intern Med 89:34–40
Koffler D, Agnello V, Winchester R, Kunkel HG (1973) The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 52:198–204
Tan EM, Schur PH, Carr RI, Kunkel HG (1966) Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45:1732–1740
Bruneau CD, Edmonds JP, Hughes GRV, Aarden LA (1977) Detection and characterisation of DNA-anti DNA complexes in patients with systemic lupus erythematosus. Clin Exp Immunol 28:433–436
Davis JS, Godfrey SM, Winfield JB (1978) Direct evidence for circulating DNA-antiDNA complexes in systemic lupus erythematosus. Arthritis Rheum 21:17–22
Townes AS, Stewart CR, Osley AG (1962) Immunologic studies of systemic lupus erythematosus. Johns Hopkins Med J 112:202–218
Schur PH (1975) Complement in lupus. Clin Rheum Dis 1:519–543
Andres GA, Accinni L, Beiser SM, Christian CL, Cinotti GA, Erlanger BF, Hsu KC, Seegal BL (1970) Localisation of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis. J Clin Invest 49:2106–2118
Krishnan C, Kaplan MH (1967) Immunopathologic studies of systemic lupus erythematosus. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis. J Clin Invest 46:569–579
Cano PO, Jerry LM, Sladowski JP, Osterland CK (1977) Circulating immune complexes in systemic lupus erythematosus. Clin Exp Immunol 29:197–204
Harkiss GD, Hazleman BL, Brown DL (1979) A longitudinal study of circulating immune complexes, DNA antibodies and complement in patients with systemic lupus erythematosus: An analysis of their relationship to disease activity. J Clin Lab Immunol 2:275–283
Cohen AS, Reynolds WF, Franklin EG (1971) Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21:643–648
Lightfoot RD, Hughes GRV (1976) Significance of persisting serologic abnormalities in systemic lupus erythematosus. Arthritis Rheum 5:837–843
Swaak AJG, Groenwold J, Aarden LA, Statius van Eps LW, Feltkamp TEW (1979) Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 22:226–235
Hurd ER, Jasin HE, Gilliam JN (1980) Correlation of disease activity and C1q binding immune complexes with the neutrophil inclusions which form in the presence of SLE sera. Clin Exp Immunol 40:283–291
Aarden LA (1977) Measurements of anti-dsDNA antibodies. Ann Rheum Dis 36:91–95
Perrin LH, Lambert PH, Miescher PA (1975) Complement breakdown products in plasma from patients with SLE and patients with membranoproliferative or other glomerulonephritis. J Clin Invest 56:165–176
Zubler RH, Lange G, Lambert PH, Miescher PA (1976) Detection of immune complexes in unheated sera by a modified 125I-C1q binding test. J Immunol 116:232–235
Nijdegger NE, Lambert PH, Gerber H, Miescher PA (1974) Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. J Clin Invest 54:297–309
Tron F, Bach JF (1977) Tests immunologiques pour le diagnostic et le prognostic du lupus erythemateux dissemine avant traitement. Nouv Presse Med 6:2573–2578
Frank MM, Hamburger MI, Lawly TJ, Kimberly RP, Plotz PH (1979) Defective reticuloendothelial system Fc receptor function in systemic lupus erythematosus. N Engl J Med 350:518–523
Abrass CK, Nies KM, Louie JS, Border WA, Glassock RJ (1980) Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 23:273–282
Inman RD, Fong JKK, Pussel BA, Ryan PJ, Hughes GRV (1980) The C1q binding assay in systemic lupus erythematosus. Arthritis Rheum 23:1282–1286
Boyd RE, Birchmore DA, Kaiser DL, Young AC, Davis JS (1983) Acute effects of steroids on immune complex profiles of patients with systemic lupus erythematosus. Arthritis Rheum 26:639–644
Perrin LH, Nydegger NE, Zubler RH, Lambert PH, Miescher PA (1977) Correlation between levels of breakdown products of C3, C4 and properdin factor B in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 20:647–652
Swaak AJG, Hannema A, Vogelaar C, Boom FA, van Es L, van Aalst R, Statius van Eps LW (1982) Determination of the half-life of C3 in patients and its relation to the presence of C3 breakdown products and/or circulating immune complexes. Rheumatol Int 2:161–166
Swaak AJG, Groenwold J, Aarden LA, Statius van Eps LW, Feltkamp TEW (1981) Prognostic value of anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 41:388–395
Davis P, Cumming RH, Verrier-Jones J (1977) Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus. Clin Exp Immunol 28:226–232
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Swaak, A.J.G., Groenwold, J., Hannema, A. et al. Correlation of disease activity with circulating immune complexes (C1QbA) and complement breakdown products (C3D) in patients with systemic lupus erythematosus. Rheumatol Int 5, 215–220 (1985). https://doi.org/10.1007/BF00541339
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541339